Scope Tea polyphenols are metabolized by the colonic microflora yielding phenolic metabolites, which may contribute to the health benefits of tea. We determined the serum and urine concentrations of phenolic acids, hippuric acid and polyhydroxyphenyl-γ-valerolactones during green tea (GT) and black tea (BT) administration. The effects of (−)-epigallocatechin gallate (EGCG) and 3,4-dihydroxyphenylacetic acid (3,4-DHPAA) alone and in combination on bioavailability, intracellular metabolism, and antiproliferative activity was determined in HCT-116 colon cancer cells. Methods and Results The concentration of phenolic metabolites was quantified by HPLC with electrochemical detection and MS. Urine concentrations of 4-hydroxyphenylacetic acid (4-HPAA), 3-hydroxyphenylacetic acid (3-HPAA) and polyhydroxy-γ-valerolactones were increased significantly in men drinking GT compared to control. Urine concentration of 3-O-methylgallic acid (3OMGA) was significantly increased in men drinking BT compared to control. Serum 3,4-DHPAA was significantly increased after consumption of GT and BT and 4-HPAA after GT consumption. In vitro treatment of HCT-116 colon cancer cells with 3,4-DHPAA and EGCG exhibited an additive antiproliferative effect, while methylation of 3,4-DHPAA was significantly decreased. 3OMGA exhibited the strongest antiproliferative activity among the phenolic acids. Conclusions The consumption of both, GT and BT, was associated with a significant increase in urinary and serum phenolic acids.
Mucormycosis is an aggressive fungal infection characterized by rapidly progressive angioinvasion and tissue necrosis. When present in the orbit, mucormycosis can quickly lead to permanent visual loss and potentially fatal cerebral extension. Orbital involvement is almost universally preceded by infection of the paranasal sinuses. Secondary infection of the orbit via direct extension of neighboring cutaneous mucormycosis has not been previously described. The authors present a case of cutaneous mucormycosis with orbital extension in a poorly controlled diabetic patient.
ObjectivesTo study the management impact that magnetic resonance imaging (MRI)-guided targeted prostate biopsies could provide relative to using only non-targeted systematic biopsies in men with clinically localized prostate cancer (PCa). Patients and MethodsA consecutive series of untreated men undergoing Artemis (MRI-ultrasonography fusion) biopsies between March 2010 and June 2013 was evaluated in this retrospective, institutional review board-approved study. Fusion biopsy included MRItargeted and systematic sampling at the same session. 3-Tesla multiparametric MRI was performed at a median of 2 weeks before biopsy. Patients were included if ≥1 systematic core was found to harbour PCa. The impact of the information obtained from targeted vs systematic biopsies was studied with regard to the following: Gleason score (GS), National Comprehensive Cancer Network (NCCN) risk reclassification, cancer core length, percentage of core positive for tumour involvement, and percentage of positive biopsy cores. ResultsThe study sample included 215 men (mean AE SD age 66 AE 8 years). The median (range) prostate-specific antigen (PSA) was 6.0 (0.7-181) ng/mL. The mean number of total biopsy samples was 18 (12 systematic and six targeted samples). Of 215 men, 34 (16%) had a higher GS on targeted vs systematic biopsy. A total of 21/183 men (12%) were stratified into a higher NCCN risk group when incorporating targeted biopsy GS results and 18/101 men (18%) were upgraded to intermediate-or high-risk from the low-risk group. Among the 34 men whose cancer severity was upgraded, increases in cancer core length, percentage of tumour involvement and percentage of cores involved were all statistically significant (P < 0.01). ConclusionTargeted prostate biopsy provided information about GS, NCCN risk and tumour volume beyond that obtained in systematic biopsies, specifically increasing the proportions of men in the intermediate-and high-risk groups. Such men may be recommended for additional treatments (pelvic nodal irradiation or hormonal therapy). The appropriateness of changing treatment because of targeted biopsy results is still unclear.
Background: Green tea (GT) contains green tea polyphenols (GTPs) which have been shown to play a role in the regulation of cell proliferation and apoptosis in prostate cancer cells in vitro and in animal models using human prostate cancer cell xenografts. GTPs are also potent scavengers of reactive oxygen species (ROS) which play a role in tumorigenesis. While there is extensive epidemiological and basic science evidence for these effects of GTPs, data from human intervention studies is much more limited. Objective: We conducted a phase II intervention study to evaluate the anticarcinogenic and antioxidant effects of green tea in prostate cancer by administering green tea in men prior to prostatectomy. Design: 79 men, diagnosed with prostate cancer and scheduled for prostatectomy, were randomized to either 6 cups of brewed green tea (GT group, N=34) or water (control group, N=33) daily for 3-8 weeks prior to surgery. 67 men completed the intervention. Blood and urine samples were collected before and after the intervention, and a section of prostate tissue was obtained following the pathology evaluation. Serum prostate specific antigen (PSA) concentration was determined by ELISA assay and prostate tissue PSA protein concentration was measured by Western blot. The prostate concentration of GTPs and their metabolites was measured using high-performance liquid chromatography (HPLC) with CoulArray electrochemical detection. The concentration of 8-hydroxydeoxyguanosine (8-OHdG), a biomarker for oxidative DNA damage, was measured in urine by HPLC. In addition, gene expression of the antioxidant enzymes superoxide dismutase (SOD) and catalase were determined in normal and tumor prostate tissue using real-time quantitative PCR. Results: Statistical analysis within each treatment arm showed that the serum PSA concentration significantly decreased in the GT group (final vs. baseline blood) (P<0.01), while no change was observed in the control group. The comparison of percent change in serum PSA between GT and control group showed a decreasing trend (p=0.085). Prostate tissue PSA protein expression was lower in men consuming GT compared to water control (p=0.06). The major bioactive component of GTPs, epigallocatechin gallate (EGCG) and its methyl metabolite 4″-O-methyl EGCG were found in prostate tissue in similar amounts, along with a small amount of epicatechin gallate. As compared to the pre-intervention level there was a significant decrease in urinary 8-OHdG concentration after GT intervention (83 vs. 50 nmol/g creatinine), while there was no change in the control group (54 vs. 55 nmol/g creatinine). Gene expression of SOD (p=0.087) and catalase (p=0.15) in the prostate tumor tissue normalized to normal prostate tissue in each individual showed a decreasing trend in men consuming GT as compared to the water control. Conclusion: The consumption of 6 cups of GT provided antioxidant protection, which may contribute to an inhibitory effect on prostate tumor growth in humans. Large-scale human intervention studies are needed to confirm these findings. Citation Format: Piwen Wang, William Aronson, Narine Abgaryan, Catherine L. Carpenter, Jaydutt V. Vadgama, David Heber, Susanne M. Henning. Antioxidant activity of green tea: A phase II clinical trial in men with prostate cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B68.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.